Blue Jet Healthcare Limited — PPTs, 29-01-2025: Investor Presentation

**Financial Highlights:**

Revenue from operations for Q3 FY25 reached ₹3,184 mn, reflecting a 52.9% QoQ increase and a notable 90.9% YoY rise. This growth was largely driven by robust sales in Pharmaceutical Intermediates. EBITDA for the quarter stood at ₹1,240 mn, up 78.5% QoQ and 127.2% YoY, with margins expanding to 39.0%. The highest-ever PAT for the quarter was recorded at ₹990 mn, marking a 69.6% QoQ and 208.3% YoY increase, resulting in a PAT margin of 31.1%.

**Strategic Initiatives and Growth Drivers:**

The company commissioned an additional manufacturing block in Ambernath focusing on Advanced Contrast Media with an investment of approximately ₹100 mn, with expected dispatches in Q4 FY25. An investment of up to ₹40 cr is planned for a new state-of-the-art R&D Centre.

**Business Developments:**

The robust performance in Q3 FY25 reflects solid demand in key product segments, particularly in contrast media and pharmaceutical intermediates, reinforcing Blue Jet Healthcare’s competitive positioning.

**Market Position and Competitive Advantage:**

Blue Jet benefits from long-standing relationships with global clients and strategic investments in capacity and technology, supporting its growth trajectory in niche pharmaceutical sectors.

**Investor Implications:**

With increasing revenue and profitability, coupled with strategic expansions, the company's outlook appears positive. Investors should consider the potential for growth in contrast media and high-intensity sweeteners sectors while monitoring operational developments.